Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124

Novartis statistics for 2026, including revenue, net income, employees, countries reached, and key facts from the latest annual report.
Novartis is a Swiss pharmaceutical company focused on innovative medicines across areas such as oncology, immunology, cardiovascular, renal, metabolism, neuroscience, and established brands. Because the company has changed meaningfully in recent years, especially after the Sandoz spin-off, the cleanest 2026 update is to focus on the latest continuing Novartis business rather than older conglomerate-era framing.
Quick Answer: Novartis generated $50.3 billion in net sales in 2024 and $11.9 billion in net income from continuing operations. The company employed about 75,883 full-time equivalent employees at year-end 2024.
| Metric | Figure | Year |
|---|---|---|
| Net sales | $50.3 billion | 2024 |
| Net income from continuing operations | $11.9 billion | 2024 |
| Employees (FTE) | 75,883 | 2024 |
| Patients reached | 250+ million | 2024 |
Novartis is one of the largest pharmaceutical companies in the world and now has a more focused structure than it did several years ago. The company’s current reporting centers on innovative medicines rather than the broader old mix that included major generics exposure.
Novartis has changed its business mix over time, and more recent reports reflect the post-Sandoz structure. That means older totals are still useful for historical context, but recent performance should be read in light of the company’s more focused pharmaceutical profile.
Novartis reported about 75,883 full-time equivalent employees at the end of 2024.
Novartis reported $50.3 billion in net sales in 2024.
Net income from continuing operations was $11.9 billion in 2024.
The company says its medicines reached more than 250 million patients in 2024.